Recardio, Inc., a San Francisco, CA_based clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, secured $3m in Series A funding.
The financing includes existing shareholders as well as a number of new undisclosed investors.
The company intends to use the funds to advance a Phase 2 clinical trial for its lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack.
Led by Dr. Roman Schenk, founder, president and CEO, Recardio is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases.
The company’s lead drug candidate, Dutogliptin, is a DPP-4 inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration.
Recardio has initiated a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.
Recardio also announced that it has relocated its headquarters from Klagenfurt, Austria, to San Francisco. The Klagenfurt location will remain as its European hub.